Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases

Toshimasa Ishizaki, Masayoshi Uehata, Ichiro Tamechika, Jeongsin Keel, Kimiko Nonomura, Midori Maekawa and Shuh Narumiya
Molecular Pharmacology May 2000, 57 (5) 976-983;
Toshimasa Ishizaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masayoshi Uehata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ichiro Tamechika
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeongsin Keel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimiko Nonomura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Midori Maekawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuh Narumiya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Y-27632 [(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride] is widely used as a specific inhibitor of the Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK) family of protein kinases. This study examined the inhibition mechanism and profile of actions of Y-27632 and a related compound, Y-30141 [(+)-(R)-trans- 4-(1-aminoethyl)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)cyclohexan-ecarboxamide dihydrochloride]. Y-27632 and Y-30141 inhibited the kinase activity of both ROCK-I and ROCK-II in vitro, and this inhibition was reversed by ATP in a competitive manner. This suggests that these compounds inhibit the kinases by binding to the catalytic site. Their affinities for ROCK kinases as determined by Ki values were at least 20 to 30 times higher than those for two other Rho effector kinases, citron kinase and protein kinase PKN. [3H]Y-30141 was taken up by cells in a temperature- and time-dependent and saturable manner, and this uptake was competed with unlabeled Y-27632. No concentrated accumulation was found, suggesting that the uptake is a carrier-mediated facilitated diffusion. Y-27632 abolished stress fibers in Swiss 3T3 cells at 10 μM, but the G1-S phase transition of the cell cycle and cytokinesis were little affected at this concentration. Y-30141 was 10 times more potent than Y-27632 in inhibiting the kinase activity and stress fiber formation, and it caused significant delay in the G1-S transition and inhibition of cytokinesis at 10 μM.

Footnotes

  • Send reprint requests to: Shuh Narumiya, Department of Pharmacology, Kyoto University Faculty of Medicine, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan. E-mail:snaru{at}mfour.med.kyoto-u.ac.jp

  • This work was supported in part by Grants-in-Aid for Specially Promoted Research (08102007) and for Scientific Research (C)(2) (10670120) from the Ministry of Education, Science, and Culture of Japan, and grants from Searle Fellowship, the Japan Foundation for Applied Enzymology, the Tanabe Medical Frontier Conference, and the Human Frontier Science Program.

  • Abbreviations:
    ROCK
    Rho-associated coiled-coil forming protein serine/threonine kinase
    BrdU
    bromodeoxyuridine
    DMEM
    Dulbecco's modified Eagle's medium
    FBS
    fetal bovine serum
    LPA
    lysophosphatidic acid
    PBS
    phosphate-buffered saline
    PKC
    protein kinase C
    Y-27632
    (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride
    Y-30141
    (+)-(R)-trans-4-(1-aminoethyl)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)cyclohexanecarboxamide dihydrochloride
    • Received August 10, 1999.
    • Accepted January 12, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 57 (5)
Molecular Pharmacology
Vol. 57, Issue 5
1 May 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases

Toshimasa Ishizaki, Masayoshi Uehata, Ichiro Tamechika, Jeongsin Keel, Kimiko Nonomura, Midori Maekawa and Shuh Narumiya
Molecular Pharmacology May 1, 2000, 57 (5) 976-983;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases

Toshimasa Ishizaki, Masayoshi Uehata, Ichiro Tamechika, Jeongsin Keel, Kimiko Nonomura, Midori Maekawa and Shuh Narumiya
Molecular Pharmacology May 1, 2000, 57 (5) 976-983;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Relapsed-Leukemia Model with NT5C2/PRPS1 Hotspot Mutations
  • The Binding Site for KCI807 in the Androgen Receptor
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics